Physician profile
John J Cudecki
NPI 1053397851
$44,115.33
in general payments reported to CMS, 2019-2025
64 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,375 · 2020: $2,876 · 2021: $2,291 · 2022: $2,612 · 2023: $7,757 · 2024: $9,990 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $9,699 · Travel and Lodging: $3,286 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,977.10 |
| Food and Beverage | $9,699.24 |
| Travel and Lodging | $3,285.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $13,694.92 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $7,799.71 | 2019-2025 | |
| Avyxa Pharma, LLC | $3,141.44 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,066.12 | 2020-2025 | Lynparza |
| Procept Biorobotics Corporation | $1,932.85 | 2019-2025 | Aquabeam System |
| Pfizer INC. | $1,914.80 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $1,605.78 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $1,418.18 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Dendreon Pharmaceuticals LLC | $787.61 | 2019-2025 | Provenge |
| Abbvie INC. | $701.46 | 2019-2025 | Botox |
| Olympus America INC. | $674.75 | 2020-2025 | Itind System, Cysto-Nephro Videoscope, Gyrus Acmi |
| Merck Sharp & Dohme LLC | $661.85 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Antares Pharma, INC. | $652.37 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Axonics, INC. | $556.94 | 2021-2023 | Axonics, Bulkamid |
| Coloplast Corp | $513.38 | 2019-2025 | Speedicath, Titan |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $481.76 | 2020-2025 | Posluma |
| Boston Scientific Corporation | $371.95 | 2019-2025 | Ams 700, Rezum Generator |
| Teleflex LLC | $370.30 | 2021-2025 | Urolift, Barrigel |
| Novartis Pharmaceuticals Corporation | $311.52 | 2022-2025 | |
| Endo Pharmaceuticals INC. | $287.21 | 2019-2023 | Xiaflex, Edex, Aveed |
| Tolmar Pharmaceuticals, INC. | $278.16 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $275.83 | 2022-2025 | Trelstar, Tlando |
| Travere Therapeutics, INC. | $251.53 | 2019-2021 | |
| Accord Healthcare, INC. | $244.15 | 2022-2024 | |
| Telix Pharmaceuticals | $207.78 | 2023-2025 | Illuccix |
| Medtronic, INC. | $194.40 | 2022-2025 | Interstim |
| Allergan, INC. | $191.57 | 2019-2022 | |
| Urogen Pharma, INC. | $188.44 | 2021-2025 | |
| Tolmar, INC. | $152.19 | 2023-2025 | Jatenzo, Eligard |
| Myovant Sciences INC. | $148.65 | 2021-2022 | |
| Urovant Sciences INC | $146.81 | 2021-2022 | |
| Angiodynamics, INC. | $142.49 | 2022 | |
| Agiliti Surgical, INC. | $126.66 | 2024-2025 | Sonablate Hifu, Koelis Trinity Fusion Biopsy System, Koelis Trinity Mri/US Fusion |
| Myriad Genetic Laboratories, INC. | $119.83 | 2021-2025 | Prolaris |
| Endo USA, INC. | $115.60 | 2024-2025 | Xiaflex, Aveed |
| Urogpo LLC | $113.09 | 2019 | |
| Amgen INC. | $109.43 | 2019-2023 | Xgeva |
| Neotract INC. | $107.00 | 2019-2020 | |
| Cardinal Health 414 LLC | $103.72 | 2022-2023 | |
| 180 Medical, INC. | $91.16 | 2022-2025 | |
| Immunitybio, INC. | $80.07 | 2025 | |
| Clarus Therapeutics INC. | $78.86 | 2021 | |
| Ambu INC. | $75.87 | 2020-2023 | |
| Clovis Oncology, INC. | $70.38 | 2020 | |
| Ferring Pharmaceuticals INC. | $62.24 | 2019-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $47.20 | 2022-2025 | |
| Profound Medical Corp. | $45.82 | 2025 | Tulsa-Pro |
| Genzyme Corporation | $42.54 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $40.28 | 2023-2025 | |
| Convatec INC. | $36.99 | 2021-2022 | |
| Foundation Medicine, INC. | $35.74 | 2021 | |
| Tempus Ai, INC | $28.59 | 2024 | Xt Cdx |
| Ethicon US, LLC | $24.45 | 2019 | |
| Novo Nordisk INC | $23.98 | 2021 | |
| Civco Medical Instruments | $23.06 | 2025 | |
| Valencia Technologies Corporation | $21.97 | 2025 | Ecoin Device Kit |
| Avation Medical, INC. | $21.30 | 2024 | Vivally |
| Abc Home Medical Supply, INC. | $21.08 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $19.64 | 2019 | |
| Halozyme INC | $18.13 | 2023 | |
| Medtronic USA, INC. | $16.70 | 2020 | |
| Aytu Biopharma, INC. | $13.84 | 2020 | |
| Coopersurgical, INC. | $13.21 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cudecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.